Class 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/44
Read and act on the official notice on GOV.UK
The defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious.
What all four recall classes mean
| Class | Action | The MHRA's definition |
|---|---|---|
| Class 1 | Immediate action | The defect presents a risk of death or disability. |
| Class 2 this recall | Action within 48 hours | The defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious. |
| Class 3 | Action within 5 days | The defect is unlikely to cause harm to the patient. |
| Class 4 | Caution in use | Usually minor defects in packaging or other printed materials. |
A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.
In plain English, for the pharmacy team
Why is this relevant to community pharmacy
Mynzepli 40 mg/mL is an eye injection medicine used by a healthcare professional. The Medicines and Healthcare products Regulatory Agency (MHRA) says the batches listed in the notice are being recalled because a small change in the finger grip could affect how the syringe is used and could risk patient safety. This affects stock held by pharmacists and dispensers, even though the product is given by a trained clinician.
What to tell patients
Use your professional judgement for each patient.
- No action is required by patients.
- If you have any questions about this medicine, seek medical attention.
- If you think you have had a side effect, report it via the MHRA Yellow Card scheme.
What needs to be done
- Stop supplying the batches listed in the notice at once.
- Quarantine any remaining stock of the batches listed in the notice.
- Return the quarantined stock to your supplier using your supplier’s approved process.
- Pharmacists: be aware that other batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe are said to be available for distribution.
- If anyone reports an adverse reaction or asks about the medicine, advise them to seek medical attention and report suspected adverse reactions via the MHRA Yellow Card scheme.
- Read and act on the official GOV.UK notice.
Pharmshark summary, checked and approved by Chris Dotchin on 1 Nov 2026. It is not the official notice: always read and act on the GOV.UK notice.
How this summary was written
An AI tool drafted it from the MHRA's own notice and nothing else. A second check compared every line with the notice. Pharmshark's clinical lead then read it against the notice, edited it where needed and approved it. If the MHRA changes the notice, this summary is taken down until it has been checked again.
The MHRA's summary
Advanz Pharma Limited are recalling specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure.
Affected batches
As listed by the MHRA, exactly as published. Always check against the GOV.UK notice before acting.
| Batch number | Expiry | Pack size | First distributed |
|---|---|---|---|
| Mynzepli 40 mg/mL solution for injection in pre-filled syringe | |||
| 2325742 | Jun-2027 | 1 | 02/01/2026 |
| 2325726 | May-2027 | 1 | 10/10/2025 |
MHRA's audience tags: Dispensing GP practices, Pharmacy